Tea Tree Oil for Health & Longevity - Quick Reference Sheet

Tea Tree Oil for Health & Longevity

Created on 10/15/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Tea tree oil is a botanical oil distilled from Australian tea tree leaves, used for targeted topical and oral-rinse hygiene of the skin, eyelids, and gums rather than systemic longevity. Trials support diluted topical use for facial acne and dandruff, while evidence for eyelid mites, gum inflammation, fungal infections, and skin bacteria is low and conflicted. Aged oil triggers allergic rashes, and oral ingestion causes nervous system poisoning. (Full Review)

Protocol

Dermatological acne and scalp regimens
5% gel (acne) or 5% shampoo (scalp)
Acne: 5% gel applied twice daily for 45–90 days; dandruff: 5% shampoo lathered for 3 minutes daily for 4 weeks
Periodontal and ocular protocols
0.2–0.5% rinse, 2.5% gel, or 7.5% lid wash
Oral: 0.2–0.5% mouthwash or 2.5% toothbrushing gel twice daily; Demodex blepharitis: 7.5% closed-eyelid shampoo scrub twice daily
Competing fungal dosing approaches
10–50% (tinea pedis) or 100% (nail)
Tinea pedis: 10% cream twice daily for scaling or 25–50% solution twice daily for cure; onychomycosis: 100% oil twice daily
Time to effect
Acne Vulgaris Lesion and Severity Reduction
6–12 weeks
Acne lesions and severity decline over 45–90 days of twice-daily 5% gel
Dandruff and Scalp Seborrheic Dermatitis Reduction
2–4 weeks
Scalp scaling and itchiness (and gingival inflammation) improve within 2–4 weeks
Cutaneous Fungal Infection (Tinea Pedis and Onychomycosis) Resolution
2–8 weeks / 6 months
Tinea pedis takes 2–8 weeks and nail fungus takes 6 months (acute histamine swelling subsides in 10–30 minutes)

Benefits

Contraindications
  • All populations (for oral ingestion)
  • Individuals with positive patch-test allergy to Melaleuca alternifolia oil, oxidized terpenes, or colophony
  • Patients with a perforated tympanic membrane (for ear instillation) or burns exceeding 10% total body surface area (TBSA)
  • Pregnant and lactating women and prepubertal children (for chronic or high-concentration use)
Key Interactions
  • CYP2A6 and CYP3A4 inhibitors (ketoconazole, ritonavir, methoxsalen) and substrates (midazolam, cyclosporine) (theoretical)
  • Topical prescription retinoids (vitamin A-derived skin-turnover drugs: tretinoin, adapalene) and antiparasitics (ivermectin, metronidazole) (theoretical)
  • Over-the-counter keratolytics (outer-skin-shedding agents: benzoyl peroxide, salicylic acid) and antiseptics (chlorhexidine) (theoretical)
  • Terpene-rich essential oils (lavender, eucalyptus, peppermint, clove oils, colophony) (theoretical)
  • Chemical peels, fractional lasers, and microneedling (theoretical)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Ocular Surface Irritation and Periocular Stinging; Intraoral Unpleasant Taste and Mucosal Burning; Cutaneous Irritation and Allergic Contact Dermatitis; Central Nervous System Depression and Ataxia After Oral Ingestion; Prepubertal Gynecomastia and Endocrine Disruption
  • Speculative: High-Frequency Cochlear Ototoxicity

Monitoring

Marker Target Why
48-Hour Cutaneous Patch Test (5–10% oil in petrolatum) Negative / Grade 0 Safety check: positive vesicular or erythematous reaction stops use.
Eyelash Demodex Mite Count (epilated lash microscopy) 0 mites per eyelash (complete eradication target) Efficacy marker: expected to decrease during eyelid scrub therapy.
Gingival Bleeding on Probing & Probing Pocket Depth <10% bleeding sites and ≤3 mm pocket depth Efficacy marker: expected to decrease with periodontal gel or rinse.
Gingival Crevicular Fluid MMP-8 No established target; track reduction from the individual's own baseline. Efficacy marker: expected to decrease alongside periodontal pocket healing.

Cadence: Baseline (including 48-hour inner-forearm patch test before initiation); cutaneous tolerance at 48 hours and 1 week; gingival, dandruff, or ocular Demodex assessment at 2 and 4 weeks; dermatological or periodontal reassessment at 6 and 12 weeks (6 months for toenail onychomycosis).

Qualitative Assessment

  • Cutaneous lesion and scaling resolution: Reduction in acne papules, foot scaling, or scalp flaking without local redness.
  • Ocular surface comfort: Resolution of morning eyelash dandruff and eyelid margin itching.
  • Gingival tissue integrity: Absence of gum bleeding during brushing without mucosal stinging.